Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Disease area: Airway diseases

Abstract

BACKGROUND: This Phase IIa study evaluated the safety and tolerability of the CXCR2 antagonist AZD5069 in patients with moderate-to-severe COPD.
METHODS: This was a 4-week, randomised, double-blind, placebo-controlled, parallel group, multi-centre study. Patients were aged 40–80 years, with a diagnosis of moderate-to-severe COPD for >1 year. Patients received placebo (PBO) bd (n=29), AZD5069 50 mg twice-daily (bd) (n=30) or AZD5069 80 mg bd (n=28) for 4 weeks. Primary safety and tolerability outcome variables included adverse events (AEs), ECG, haematology, clinical chemistry, urinalysis, vital signs, and lung function. The pharmacokinetics (PK) of AZD5069 and the effect of exposure on circulating neutrophils were assessed as secondary objectives.
RESULTS: Patients had a mean age of 64 years (69% male; all white). There were no deaths. Two SAEs (one with 50 mg and one with 80 mg) were assessed by the investigator as not related to AZD5069. The number of patients with AEs was evenly distributed across treatment groups. Discontinuation due to AEs was also similar across treatment groups, but highest in patients receiving AZD5069 50 mg (3, 5 and 2 patients receiving PBO, AZD5069 50 mg and 80 mg respectively). The PK was as predicted from healthy volunteers, but with higher variability. As expected, there was an exposure-related, reversible reduction in circulating neutrophils with AZD5069. No other clinically important changes in primary variables, including infection rates, were observed with AZD5069.
CONCLUSIONS: AZD5069 was well tolerated with no safety issues identified in this 4 week Phase IIa COPD patient trial.

Rating:

Share or cite this content

Citations should be made in the following way:
A.M. Kirsten, K. Förster, E. Radeczky, A. Linnhoff, B. Balint, H. Watz, H. Wray, L. Salkeld, M. Cullberg, H. Lam, B. Larsson (Grosshansdorf, Berlin, Germany; Százhalombatta, Deszk, Hungary; Mölndal, Södertälje, Sweden). The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD. Eur Respir J 2012; 40: Suppl. 56, 3083

Member's Comments

No comment yet.

Related content which might interest you: Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007 Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Safety and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β2-agonist, in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009 Efficacy and safety of BI 671800, an oral CRTH2 antagonist in controller naïve patients with poorly-controlled asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006 Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006 Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007 Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study}, Source: Eur Respir J 2012; 40: 830-836 Year: 2012 Single-dose indacaterol, a novel 24-hour β2-agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 The efficacy and safety of long-acting muscarinic antagonist treatment for COPD Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma Year: 2019